Achillion climbs on ACH-3102 data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $0.84 to $11.66 on Monday after it said 100% of HCV genotype 1 patients receiving ACH-3102 plus

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE